Global Montelukast Intermediate Market

Montelukast Intermediate Comprehensive Study by Application (Asthma, Allergic rhinitis, Bronchospasm, Urticaria) Players and Region - Global Market Outlook to 2030

Montelukast Intermediate Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Montelukast Intermediate
Montelukast is a medication used in the treatment of asthma, allergic rhinitis, bronchospasm, and urticaria. Increasing prevalence of asthma driving the demand for montelukast intermediate. For instance, according to the World Health Organizations (WHO), 235 million people are currently suffering from asthma. Further, growing healthcare infrastructure in the developing economies and rising demand for active pharmaceutical ingredients expected to drive the demand for montelukast intermediate market over the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Montelukast Intermediate market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Montelukast Intermediate Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that China, India, United States Players will contribute the maximum growth to Global Montelukast Intermediate market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Sharp & Dohme Corp. (United States), Morepen Laboratories (India), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States) and Zhuhai Tianjian Chemical Co., Ltd. (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Manus Aktteva Biopharma LLP (India), Titan Pharma (India) Pvt Ltd. (India) and Shanghai Yijing Industrial Co., Ltd. (China).

Segmentation Overview
AMA Research has segmented the market of Global Montelukast Intermediate market by , Application (Asthma, Allergic rhinitis, Bronchospasm and Urticaria) and Region.



On the basis of geography, the market of Montelukast Intermediate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increasing Applications of Montelukast Intermediate in the Treatment of Allergic Rhinitis

Market Growth Drivers:
Rising Demand for Active Pharmaceutical Ingredients and Increasing Number of Patients with Respiratory Diseases

Challenges:
Side Effects Such As Diarrhea, Vomiting, and Others

Restraints:
Stringent Government Regulations Regarding Montelukast Intermediate and High Manufacturing Cost of Active Pharmaceutical Ingredients

Opportunities:
Increasing Number of Patients with Asthma and Growing Pharmaceutical Industry in the Developing Economies


“According to the Therapeutic Goods Administration, Montelukast which is marketed in Australia under the brand name Singulair and multiple generic brands, is used to prevent and treat chronic asthma in adults and children aged two years and older. It can also be used for the symptomatic treatment of seasonal hayfever. It has been listed on the Pharmaceutical Benefits Scheme as a single preventative medicine for the treatment of mild persistent or frequent intermittent asthma in children/adolescents aged 2 to 14 years. It is also listed on the PBS for the prevention of exercise-induced asthma in children/adolescents aged 6 to 14 years.”

Key Target Audience
Montelukast API Manufacturer, Academic and Research Institutes, Pharmaceutical Manufacturers, Reference Laboratories, Pharmaceutical Raw Materials Suppliers, Montelukast Intermediate Manufacturers, Market Research and Consulting Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Asthma
  • Allergic rhinitis
  • Bronchospasm
  • Urticaria
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Active Pharmaceutical Ingredients
      • 3.2.2. Increasing Number of Patients with Respiratory Diseases
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Such As Diarrhea, Vomiting, and Others
    • 3.4. Market Trends
      • 3.4.1. Increasing Applications of Montelukast Intermediate in the Treatment of Allergic Rhinitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Montelukast Intermediate, by Application and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Montelukast Intermediate (Value)
      • 5.2.1. Global Montelukast Intermediate by: Application (Value)
        • 5.2.1.1. Asthma
        • 5.2.1.2. Allergic rhinitis
        • 5.2.1.3. Bronchospasm
        • 5.2.1.4. Urticaria
      • 5.2.2. Global Montelukast Intermediate Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Montelukast Intermediate (Price)
  • 6. Montelukast Intermediate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Sharp & Dohme Corp. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Morepen Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Zhuhai Tianjian Chemical Co., Ltd. (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Montelukast Intermediate Sale, by Application and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Montelukast Intermediate (Value)
      • 7.2.1. Global Montelukast Intermediate by: Application (Value)
        • 7.2.1.1. Asthma
        • 7.2.1.2. Allergic rhinitis
        • 7.2.1.3. Bronchospasm
        • 7.2.1.4. Urticaria
      • 7.2.2. Global Montelukast Intermediate Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Montelukast Intermediate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Montelukast Intermediate: by Application(USD Million)
  • Table 2. Montelukast Intermediate Asthma , by Region USD Million (2018-2023)
  • Table 3. Montelukast Intermediate Allergic rhinitis , by Region USD Million (2018-2023)
  • Table 4. Montelukast Intermediate Bronchospasm , by Region USD Million (2018-2023)
  • Table 5. Montelukast Intermediate Urticaria , by Region USD Million (2018-2023)
  • Table 6. South America Montelukast Intermediate, by Country USD Million (2018-2023)
  • Table 7. South America Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 8. Brazil Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 9. Argentina Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 10. Rest of South America Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 11. Asia Pacific Montelukast Intermediate, by Country USD Million (2018-2023)
  • Table 12. Asia Pacific Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 13. China Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 14. Japan Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 15. India Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 16. South Korea Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 17. Taiwan Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 18. Australia Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 19. Rest of Asia-Pacific Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 20. Europe Montelukast Intermediate, by Country USD Million (2018-2023)
  • Table 21. Europe Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 22. Germany Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 23. France Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 24. Italy Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 25. United Kingdom Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 26. Netherlands Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 27. Rest of Europe Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 28. MEA Montelukast Intermediate, by Country USD Million (2018-2023)
  • Table 29. MEA Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 30. Middle East Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 31. Africa Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 32. North America Montelukast Intermediate, by Country USD Million (2018-2023)
  • Table 33. North America Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 34. United States Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 35. Canada Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 36. Mexico Montelukast Intermediate, by Application USD Million (2018-2023)
  • Table 37. Company Basic Information, Sales Area and Its Competitors
  • Table 38. Company Basic Information, Sales Area and Its Competitors
  • Table 39. Company Basic Information, Sales Area and Its Competitors
  • Table 40. Company Basic Information, Sales Area and Its Competitors
  • Table 41. Company Basic Information, Sales Area and Its Competitors
  • Table 42. Montelukast Intermediate: by Application(USD Million)
  • Table 43. Montelukast Intermediate Asthma , by Region USD Million (2025-2030)
  • Table 44. Montelukast Intermediate Allergic rhinitis , by Region USD Million (2025-2030)
  • Table 45. Montelukast Intermediate Bronchospasm , by Region USD Million (2025-2030)
  • Table 46. Montelukast Intermediate Urticaria , by Region USD Million (2025-2030)
  • Table 47. South America Montelukast Intermediate, by Country USD Million (2025-2030)
  • Table 48. South America Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 49. Brazil Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 50. Argentina Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 51. Rest of South America Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 52. Asia Pacific Montelukast Intermediate, by Country USD Million (2025-2030)
  • Table 53. Asia Pacific Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 54. China Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 55. Japan Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 56. India Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 57. South Korea Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 58. Taiwan Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 59. Australia Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 60. Rest of Asia-Pacific Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 61. Europe Montelukast Intermediate, by Country USD Million (2025-2030)
  • Table 62. Europe Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 63. Germany Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 64. France Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 65. Italy Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 66. United Kingdom Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 67. Netherlands Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 68. Rest of Europe Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 69. MEA Montelukast Intermediate, by Country USD Million (2025-2030)
  • Table 70. MEA Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 71. Middle East Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 72. Africa Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 73. North America Montelukast Intermediate, by Country USD Million (2025-2030)
  • Table 74. North America Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 75. United States Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 76. Canada Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 77. Mexico Montelukast Intermediate, by Application USD Million (2025-2030)
  • Table 78. Research Programs/Design for This Report
  • Table 79. Key Data Information from Secondary Sources
  • Table 80. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Montelukast Intermediate: by Application USD Million (2018-2023)
  • Figure 5. South America Montelukast Intermediate Share (%), by Country
  • Figure 6. Asia Pacific Montelukast Intermediate Share (%), by Country
  • Figure 7. Europe Montelukast Intermediate Share (%), by Country
  • Figure 8. MEA Montelukast Intermediate Share (%), by Country
  • Figure 9. North America Montelukast Intermediate Share (%), by Country
  • Figure 10. Global Montelukast Intermediate share by Players 2023 (%)
  • Figure 11. BCG Matrix for key Companies
  • Figure 12. Merck Sharp & Dohme Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 13. Merck Sharp & Dohme Corp. (United States) Revenue: by Geography 2023
  • Figure 14. Morepen Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 15. Morepen Laboratories (India) Revenue: by Geography 2023
  • Figure 16. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 17. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 18. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 20. Zhuhai Tianjian Chemical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 21. Zhuhai Tianjian Chemical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 22. Global Montelukast Intermediate: by Application USD Million (2025-2030)
  • Figure 23. South America Montelukast Intermediate Share (%), by Country
  • Figure 24. Asia Pacific Montelukast Intermediate Share (%), by Country
  • Figure 25. Europe Montelukast Intermediate Share (%), by Country
  • Figure 26. MEA Montelukast Intermediate Share (%), by Country
  • Figure 27. North America Montelukast Intermediate Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck Sharp & Dohme Corp. (United States)
  • Morepen Laboratories (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mylan N.V. (United States)
  • Zhuhai Tianjian Chemical Co., Ltd. (China)
Additional players considered in the study are as follows:
Manus Aktteva Biopharma LLP (India) , Titan Pharma (India) Pvt Ltd. (India) , Shanghai Yijing Industrial Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Mar 2024 210 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Montelukast Intermediate Market Quantitative research analysis
Global Montelukast Intermediate Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Sharp & Dohme Corp. (United States), Morepen Laboratories (India), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States) and Zhuhai Tianjian Chemical Co., Ltd. (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Applications of Montelukast Intermediate in the Treatment of Allergic Rhinitis" is seen as one of major influencing trends for Montelukast Intermediate Market during projected period 2023-2030.
The Montelukast Intermediate market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Montelukast Intermediate Market Report?

Have a Query? Click Here

Other Related Reports

Oral Thrush Comprehensive Study by Type (Pseudomembranous, Erythematous, Hyperplastic, Others), Application (Hospitals, Clinics), Diagnosis Methods (Examination, Biopsy, Endoscopy, Others.), Treatmen...
$ 3450
Treatment for Communicable Diseases Comprehensive Study by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others), Vaccines), Application (Hospital, Clinic, Other), Diseases...
$ 3750
Injectable Anti-Wrinkle Comprehensive Study by Type (Muscle Relaxants (Botox Injections, Others), Synthetic Wrinkle Fillers (Sculptra, Radiesse, Silicone), Autologous Wrinkle Fillers, Muscle Relaxant...
$ 3750
Unna Boot Comprehensive Study by Application (Venous Leg Ulcers, Lymphedema, Eczema), Raw Material (Zinc Oxide, Zinc, Calamine), Distribution Channel (Offline Retail, Online Retail) Players and Regi...
$ 3500
RNA Based Therapeutics Comprehensive Study by Application (Cardiovascular, Kidney Diseases, Oncology, Infectious Diseases, Metabolic Disorders, Others), Technology (Inhibition, Microarrays, Labeling,...
$ 3650
Cancer Biological Therapy Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors), Application (Hospitals, Diagnostic Laboratories, Research &...
$ 3650